O Brien Greene & Co. Inc Sells 98 Shares of Axon Enterprise, Inc $AXON

O Brien Greene & Co. Inc lowered its position in Axon Enterprise, Inc (NASDAQ:AXON) by 4.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,144 shares of the biotechnology company’s stock after selling 98 shares during the quarter. O Brien Greene & Co. Inc’s holdings in Axon Enterprise were worth $1,775,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of AXON. Westside Investment Management Inc. raised its stake in Axon Enterprise by 4.8% in the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 13 shares during the period. CVA Family Office LLC raised its position in shares of Axon Enterprise by 26.9% in the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 14 shares during the period. LaSalle St. Investment Advisors LLC lifted its stake in shares of Axon Enterprise by 2.1% during the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock worth $408,000 after buying an additional 16 shares during the last quarter. Hemington Wealth Management grew its stake in Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares during the last quarter. Finally, Washington Trust Advisors Inc. boosted its holdings in shares of Axon Enterprise by 44.7% during the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 17 shares during the period. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Bank of America lifted their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Northland Securities set a $800.00 price objective on Axon Enterprise in a research report on Tuesday, August 5th. Raymond James Financial reiterated an “outperform” rating and issued a $855.00 target price (up from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, The Goldman Sachs Group dropped their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research report on Wednesday. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $810.71.

Insider Buying and Selling at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 77 shares of the company’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total value of $58,520.00. Following the transaction, the chief accounting officer owned 15,003 shares of the company’s stock, valued at approximately $11,402,280. This represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Joshua Isner sold 15,919 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the completion of the sale, the president directly owned 238,379 shares in the company, valued at $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 59,932 shares of company stock worth $45,115,616. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Down 8.2%

AXON stock opened at $587.14 on Friday. The firm has a market capitalization of $46.09 billion, a PE ratio of 144.97, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a twelve month low of $462.81 and a twelve month high of $885.91. The stock’s 50 day moving average is $722.51 and its 200-day moving average is $734.37.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.